Lipid‐Lowering Efficacy, Safety, and Costs of a Large‐Scale Therapeutic Statin Formulary Conversion Program

Pharmacotherapy - Tập 21 Số 9 - Trang 1130-1139 - 2001
Allen J. Taylor1, Karen A. Grace2, Jennifer Swiecki2, Richard Hyatt2, Henry Gibbs2, Munazza Sheikh2, Patrick G. O’Malley3, Susan Pitman Lowenthal4, Mark West2,4, John Spain2, Kent Maneval2, David L. Jones3
1Cardiology, Walter Reed Army Medical Center, Washington, D.C.
2Department of Medicine, and the Department of Pharmacy, Walter Reed Army Medical Center, Washington, D.C
3General Internal Medicine Services, Walter Reed Army Medical Center, Washington, D.C
4Scientific Relations Division, Bayer Pharmaceutical Corporation, West Haven, Connecticut

Tóm tắt

Study Objective. To assess the lipid‐lowering efficacy, safety, and costs of a large‐scale statin formulary conversion program.Design. Prospective, observational study.Setting. Tertiary academic medical center.Patients. A total of 980 patients consented to participate; 942 patients completed the study.Intervention. Patients were converted from their current statin therapy to either cerivastatin 0.4 or 0.8 mg/day, or simvastatin 80 mg/day, using a conversion algorithm.Measurements and Main Results. Efficacy and safety were evaluated at baseline and after 6 weeks of therapy; costs were also measured. Overall attainment of the National Cholesterol Education Program (NCEP) goal for low‐density lipoprotein cholesterol (LDL) increased from 64.8% to 74.5% of patients (p<0.001); mean LDL decreased from 115 ± 30 mg/dl to 106 ± 25 mg/dl (p<0.001). Adverse events occurred in 3% of patients, and included myositis (0.6%) and increased hepatic transaminases (0.1%). Overall costs were reduced by $115/patient treatment‐year.Conclusion. Statin therapeutic interchange can improve lipid control at reduced costs. The possibility of uncommon but potentially serious adverse effects suggests that these programs require appropriate monitoring.

Từ khóa


Tài liệu tham khảo

Scandinavian Simvastatin Survival Study Group., 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S), Lancet, 344, 1383

10.1001/jama.279.20.1615

10.1056/NEJM199811053391902

10.1056/NEJM199701163360301

The MAAS Study Group., 1994, Effect of simvastatin on coronary atheroma: the multicentre anti‐atheroma study (MAAS). [published erratum appears in Lancet 1994;344(8924):762], Lancet, 344, 633

10.1056/NEJM199610033351401

10.1056/NEJM199511163332001

10.1023/A:1007765723962

10.1016/S0140-6736(05)79893-7

10.1016/S0163-7258(98)00016-3

10.1007/s002280050566

10.1161/01.CIR.89.3.1333

Pisani T., 1995, Accurate direct determination of low‐density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay, Arch Pathol Lab Med, 119, 1127

Fugit R.V., 2000, Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic, Am J Health-Syst Pharm, 57, 1703, 10.1093/ajhp/57.18.1703

Patel R.J., 1999, Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center, Am J Manag Care, 5, 465

10.1177/147323000002800201

10.1016/S0735-1097(98)00300-3

10.1016/S0002-9149(98)00435-4

10.1016/S0002-9149(98)00436-6

10.2165/00019053-199814003-00004

10.1016/S0002-9149(97)00965-X

10.2165/00003088-200039020-00002

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 21 Số 9

1130-1139

Thông tin tác giả